tert-Butyl ((1-methylpiperidin-4-yl)methyl)carbamate | 1420853-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-Butyl ((1-methylpiperidin-4-yl)methyl)carbamate
• 英文别名: tert-butyl N-[(1-methylpiperidin-4-yl)methyl]carbamate
• CAS: 1420853-41-3
• 化学式: C₁₂H₂₄N₂O₂
• 分子量: 228.335
• InChiKey: DQWOOANNVFWGLH-UHFFFAOYSA-N

物化性质

• 沸点：
  317.0±15.0 °C(Predicted)
• 密度：
  0.978±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  tert-Butyl ((1-methylpiperidin-4-yl)methyl)carbamate 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 以1.2 g的产率得到(1-methylpiperidin-4-yl)methanamine hydrochloride
  参考文献：
  名称：

  Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors

  摘要：

  We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[ 4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3K alpha lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.035
• 作为产物：
  描述：

  4-(叔丁氧羰基氨基甲基)吡啶 在 platinum(II) oxide 、 氢气 作用下， 以 甲醇 、 乙腈 为溶剂， 100.0 ℃ 、275.8 kPa 条件下， 反应 20.17h， 生成 tert-Butyl ((1-methylpiperidin-4-yl)methyl)carbamate
  参考文献：
  名称：

  Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors

  摘要：

  We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[ 4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3K alpha lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.035

文献信息

• [EN] LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY<br/>[FR] DÉRIVÉS DE THIOPHÈNE 2,5-DISUBSTITUÉS DE FAIBLE POIDS MOLÉCULAIRE ET LEUR UTILISATION EN THÉRAPIE
  申请人：NOVASAID AB

  公开号：WO2009098282A1

  公开（公告）日：2009-08-13

  A compound of formula (I). The compound is useful for the treatment of disorders such as pain, fever, inflammation and cancer. A method for preparing the compound.

  一种化合物的化学式（I）。该化合物可用于治疗疼痛、发热、炎症和癌症等疾病。一种制备该化合物的方法。
• ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF
  申请人：Ohno Michihiro

  公开号：US20100016319A1

  公开（公告）日：2010-01-21

  This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

  本发明涉及一种药物，其有效成分为以下式子所示的芳基亚甲基脲或其药学上可接受的盐： 该芳基亚甲基脲及其药学上可接受的盐可用于治疗或预防炎症性肠病和过度活跃的膀胱。
• TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
  申请人：Allen Shelley

  公开号：US20110144100A1

  公开（公告）日：2011-06-16

  Compounds of Formula (I): I in which B, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 and R 11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

  式(I)的化合物：其中B、R1、R1a、R2、R3、R4、R5、R6、R7、R10和R11具有规范中给定的含义，是用于治疗由PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病的受体酪氨酸激酶抑制剂。
• QUINOLONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160060276A1

  公开（公告）日：2016-03-03

  The invention relates to antibacterial compounds of formula I wherein R 1 , U, V and A are as defined in the description, to pharmaceutical compositions containing them and uses of these compounds in the manufacture of medicaments for the treatment of bacterial infections.

  本发明涉及一种式子为I的抗菌化合物，其中R1、U、V和A的定义如描述中所述，以及含有它们的药物组合物和使用这些化合物制造治疗细菌感染的药物。
• [EN] NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE<br/>[FR] NOUVELLES PURINE-2,6-DIONES FONCTIONNALISÉES ET UTILISATION CORRESPONDANTE EN MÉDECINE
  申请人：THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING

  公开号：WO2019020828A9

  公开（公告）日：2019-04-11